Tzvi Palash joined Gamida Cell’s leadership team as chief operating officer in July 2018, bringing more than 30 years of expertise in commercial operations in the healthcare industry to his role. Prior to joining Gamida Cell, Tzvi served as COO at Protalix Biotherapeutics, Inc., where he led all operational activities through the company’s FDA approval of plant cell culture produced protein product, Elelyso®. Prior to joining Protalix, Tzvi served as a general manager at ColBar LifeScience Ltd, a biomaterial company acquired by Johnson & Johnson, where he led the planning, construction, scale-up and regulatory oversight of its Israel-based manufacturing facility. He also successfully led FDA audits for Evolence® and Ossix® and was a member of the Global Aesthetic Management Team within the Consumer Group of Johnson & Johnson. Earlier in his career, Tzvi held operational roles at Teva Pharmaceutical Industries and Interpham Laboratories.
Tzvi holds a B.S. in biology from Tel Aviv University and an M.Sc. in biochemistry from Jerusalem University.